If you've watched your pharmacy gross margin shift from one quarter to the next without changing a single thing at the dispensary counter, you've seen Category M in action. The reimbursement price of generic medicines isn't set by you. DHSC sets it centrally, aiming to give the whole pharmacy sector the margin the contract funds, and changes it each quarter when the sector is earning above or below that level.
When the sector has earned too much, the correction comes through lower prices in later quarters, and that's what the trade calls the clawback. Understanding it is the starting point for using your monthly accounts as a management tool rather than a compliance exercise, and it's why margin variance analysis, the thing a specialist watches, is the core monthly job.
Note: The Drug Tariff, Category M included, covers England and Wales; the contract settlement figures here are England's. Scotland and Northern Ireland have their own arrangements.
Category M and clawbacks: the short answer
Category M is the part of the NHS Drug Tariff that sets the reimbursement price of readily available generic medicines. DHSC sets the prices from suppliers' price information, aiming to give the pharmacy sector the margin the contract funds: £1.1 billion in 2026/27 (CPCF 2026/27 letter). When the medicine margin survey shows the sector earning more than that, later quarters' prices are set lower to recover the excess; when it's earning less, prices go up. That forward recovery is the clawback. Nothing you've already dispensed is repriced.
The practical consequence is that your pharmacy gross margin is set centrally and moves quarter by quarter, regardless of what happens at your counter. This is not a marginal quirk: it is the defining feature of how pharmacy income works, and it is why a pharmacist's monthly accounts need to be read as a variance report, not just a profit figure.
Want this checked against your specific situation?
Leave your details and a one-line summary. One of our specialists will come back to you, with no obligation.
Where pharmacy margin comes from
Before looking at Category M specifically, it helps to be clear about the ground the margin sits on. Pharmacy income under the NHS is contract-driven, not till-driven. It is reimbursement at Drug Tariff prices plus remuneration (dispensing fees and service payments) under the Community Pharmacy Contractual Framework (CPCF). The turnover figure in a pharmacy's accounts looks like a retail number but it behaves like a contract income number. (How the whole income model fits together, fees and the 2026/27 settlement included, is in how pharmacies make money.)
That distinction matters because the margin that sits on top of that income is also contract-derived. Unlike a retailer who buys stock at one price and sells at another price they set themselves, a pharmacy dispenses generics at a Drug Tariff reimbursement price that DHSC sets, and the gap between that price and the actual cost of buying the stock is what constitutes the Category M margin.
| Income type | Who sets the margin | Adjusted retrospectively? |
|---|---|---|
| Retail OTC sales | You (your markup) | No |
| Category M generic dispensing | DHSC, each quarter | No: over-delivered margin is recouped through later quarters' prices (the clawback) |
| Branded and appliance dispensing | Set by Drug Tariff category | Varies by category |
| Remuneration fees (dispensing, services) | CPCF negotiation | No (fixed per fee schedule) |
Sources: CPCF (England.nhs.uk), Drug Tariff (NHSBSA) and the CPCF 2026/27 letter (gov.uk).
What Category M does
Category M covers the reimbursement price of readily available generic medicines. DHSC sets these prices from information suppliers have to give it under the Health Service Products (Provision and Disclosure of Information) Regulations 2018, and NHSBSA publishes them in the Drug Tariff for DHSC. The aim is the margin the contract funds for the whole sector, £1.1 billion in 2026/27. That's a collective amount for the sector, not a guaranteed margin for any one pharmacy.
Prices in the Drug Tariff normally change once a quarter, in the January, April, July and October editions. Each change reflects two things: how market prices moved in an earlier quarter, and an adjustment in light of the medicine margin survey, which measures what pharmacies actually paid. October 2026's change, for example, reflected price movements in April to June 2026 and an upward adjustment to margin of £14.5 million a quarter after the survey for January to March 2026 (NHSBSA's Category M page). Generic prices keep moving in the wholesale market between those changes, so the listed price is always an approximation of what you pay. The quarterly adjustment is how the system corrects it, going forward.
Category M is one category within the Drug Tariff and should not be conflated with the Drug Tariff as a whole. For a broader explanation of how the Drug Tariff is structured and how changes to it are announced, see our post on Drug Tariff changes explained.
What the clawback is
Clawback is the trade word for recovering margin the sector has earned above the funded level. It isn't a bill, and it doesn't reprice what you've already dispensed: you're paid the price "listed in the Drug Tariff" for the month you dispense (Part II Clause 8A). It works forward. When the margin survey shows the sector has earned more than intended (because wholesale prices fell faster than the Tariff caught up, say), DHSC sets later quarters' Category M prices lower to recover the excess. While that recovery is running, the Tariff says "the Department may constrain concessionary prices so as not to undermine this recouping" (Clause 8B).
The mechanism works in reverse too. When the sector earns below the intended level (because wholesale prices rose faster than the Tariff captured), prices are adjusted upward. And where something does look back, it runs in your favour: concessionary prices can be agreed after the month they cover, and each quarter, where DHSC considers it appropriate, NHSBSA pays a top-up to concessionary prices granted three quarters before (Clause 8F).
The flow looks like this:
- The contract sets the margin the sector should keep for the year (£1.1 billion in 2026/27).
- DHSC sets Category M prices from suppliers' price information, before the quarter starts.
- Actual wholesale buying prices move away from that assumption, and the medicine margin survey measures by how much.
- If the sector earned more than funded, later quarters' prices are set lower to recover it; if less, higher.
- Your reimbursement per item changes from the next quarter without anything changing at your counter.
Source: NHSBSA Drug Tariff (Part II Clauses 8A, 8B and 8F; Part VIIIA).
Prices normally change once a quarter, so you know when to look. What you can't know in advance is the size or direction of each change, which is one reason monthly tracking matters more than an annual accounts review.
So what was the latest Category M clawback? For 2026/27, there isn't one. The settlement (joint letter of 29 May 2026) writes off £219 million of confirmed historic over-delivery up to 30 September 2025 (£166 million net of historic fee under-delivery), and up to £73 million more for October 2025 to March 2026, subject to the margin survey. It also says "no price adjustments will be made in 2026 to 2027 to recover any remaining over-delivery from 2025 to 2026". The margin adjustments DHSC has announced for 2026/27 have all gone up: £20 million in April 2026, then £24.3 million a quarter from July and £14.5 million a quarter from October. The last downward one was in January 2026: £16.8 million a quarter, taken about half from Category M and half from Category A (NHSBSA's Category M page).
Why your margin can drop with no change at the counter
Here's how it shows up. The gross margin percentage in the month-end accounts has moved, nothing was done differently, and the bookkeeper or accountant has no explanation beyond "it's just how it went".
There are two overlapping reasons this happens.
First, the quarterly price change. Each quarter's new Category M prices reflect market movements and, when over-delivery is being recovered, the clawback (not in 2026/27). A downward change lands in your accounts as a reduction in reimbursement income per item, which compresses gross margin without any change in dispensing volume or buying behaviour.
Second, dispensing mix shift. Category M covers generics, and your dispensing mix (which items you dispensed and how many of each) changes month to month as prescriptions change. If your mix shifted toward items with lower Category M margins in a given period, your blended gross margin falls even if the Drug Tariff prices held steady. This is a mix effect, not a clawback, but it looks identical in the accounts unless you break the margin down by item category.
Because the reimbursement price is set centrally and changed each quarter, the margin isn't in your control the way a retail markup is. What is in your control is how quickly and accurately you identify which of these forces drove a given month's variance.
The core monthly job: margin variance analysis
Standard bookkeeping for a pharmacy records income and costs correctly and produces an accurate profit figure. That is necessary but not sufficient. The question the accounts need to answer is: why did the margin move, and is the movement a Category M adjustment, a mix shift, a volume change, or a reconciliation error?
Margin variance analysis is the process of answering that question systematically. It compares actual gross margin in a period against what the central reimbursement prices implied the pharmacy should have earned, and against a sector benchmark. The gap between actual and expected reveals where money leaked or was recovered.
This matters for several practical reasons.
- A clawback adjustment that is not identified will be mistaken for a performance problem. If margin falls because of a central price adjustment and the owner does not know this, they may make operating decisions (changing staff hours, cutting stock orders) in response to a signal that does not reflect their own performance.
- A mix-driven margin fall points to a different response than a clawback. A mix effect suggests looking at the dispensing profile; a clawback is a sector-level event that requires context to assess.
- Reconciliation errors in FP34 submissions can suppress income. These look like margin falls but are recoverable. Without variance analysis they stay hidden.
- Benchmarking against sector margin norms identifies whether a pharmacy's buying is competitive. Two pharmacies with identical Category M reimbursement can have different actual margins if their buying prices differ. The variance analysis isolates this.
The practical monthly job is therefore not recording what happened but understanding why it happened and whether the movement is structural, cyclical, or recoverable.
What a specialist watches
A pharmacy specialist reviewing the monthly accounts looks at a set of questions that a general bookkeeping review does not address.
Which lines moved? Gross margin on generics moves differently from margin on branded items, appliances, or OTC retail. A blended margin figure hides what is actually driving the variance. The first step is to break out the Category M component of dispensing income and look at it separately.
Is this a Category M adjustment or a mix effect? A central reimbursement price change affects all items in a category across the sector. A mix effect is specific to your dispensing profile that month. These two causes require different responses and should not be conflated.
Is the pharmacy tracking to sector benchmark? Comparing actual Category M margin to the sector level indicates whether the pharmacy's buying is in line with the sector average that the Drug Tariff pricing assumes, or whether there is a structural gap. A persistent gap below benchmark suggests a buying problem or a mix that is systematically less favourable than the sector average.
Are there FP34 reconciliation anomalies? Income from NHS dispensing flows through the FP34 submission cycle: NHSBSA pays a 100% estimated advance around the 10th of the following month and settles the balance about two months after you submit. A mismatch between submissions and payments can suppress income in the accounts. This needs to be tracked separately from the margin calculation. For more on the cash-flow timing side, see our post on how the FP34 payment cycle works.
Is service income (Pharmacy First and similar) being accounted for separately? Service income is a growing revenue line with its own fee structure and thresholds, and should be tracked distinctly from dispensing margin. Mixing it into a blended margin figure distorts both lines.
Getting on top of your margin
Category M means the gross margin figure in your monthly accounts is produced by forces partly outside your control. The response to that is not passivity but measurement. Knowing exactly which component of a margin movement is a central adjustment, which is a mix effect, and which is recoverable through better buying or reconciliation is what separates a pharmacy that manages its finances from one that records them.
For pharmacy owners who want to benchmark their actual Category M margin against sector norms, identify mix effects early, and have reconciliation checked monthly rather than annually, our pharmacy benchmarking and margin service is built around this specific problem. It is the practical answer to a margin that moves on its own.
Owners looking at the wider picture of NHS contract income, from the FP34 payment cycle to Pharmacy First service income accounting, can also speak to us about how these lines fit together into a complete monthly management accounts picture. Use the contact form to start the conversation.